Early data in patient-derived primary tumors suggest that VSIG4 antibodies could generate a greater anti-tumor inflammatory response compared to current immunotherapies in both PD-1 responsive and non-responsive tumors.
Recently, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (referred to as “Sunshine Guojian”) was awarded the Grade A Quality Credit Unit in the 2019 quality credit rating assessment of Shanghai pharmaceutical manufacturing enterprises after a series of strict and comprehensive reviews and assessments.
YISAIPU, an antibody drug independently developed by Sunshine Guojian Pharmaceuticals (Shanghai) Co., Ltd., a subsidiary of 3SBio,
Numab Therapeutics announced today the closing of its Series B financing round at a total volume of CHF 22M (approximately USD 22.6M).
China's leading biopharmaceutical company, announced today that Recombinant Humanized Anti-Interleukin-5 (IL-5) Monoclonal Antibody Injection (hereinafter referred to as 610) independently developed by its subsidiary
YISAIPU, an antibody drug independently developed by Sunshine Guojian Pharmaceuticals (Shanghai) Co., Ltd., a subsidiary of 3SBio,
On January 10, 2020, the annual gathering and the award ceremony for outstanding enterprises in Zhangjiang Science City was held in Zhangjiang,
Recently, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. stood out among more than 30,000 enterprises in the city, and was awarded as one of “50 Outstanding Enterprises Observing Contract and Valuing Credit”. It is also one of the only two pharmaceutical enterprises obtaining this award.
On January 2, 2020, a symposium and an awarding ceremony were held for sci-tech innovation bases of Shanghai’s private enterprises. At the symposium, 10 private technology enterprises with outstanding technological achievements were selected to build up 10 technology innovation centers in Shanghai. Among them, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. was selected to build the Shanghai Antibody Technology Innovation Center.
Sunshine Guojian announced recently that Xenopax, the only humanized anti-CD25 monoclonal antibody injection approved for marketing in China, has been officially launched. The monoclonal antibody drug is independently developed by Sunshine Guojian and used for prevention of acute rejection after renal transplantation. It can be combined with the routine immunosuppression regime to significantly improve the survival rate of transplanted organs and the quality of life of patients.
SHENYANG, China, SHANGHAI, China, and WAEDENSWIL, Switzerland — December [12], 2019 — 3SBio Inc. (“3SBio”, HKEX:1530) and Numab Therapeutics (“Numab”) announced today on a collaboration agreement, pursuant to which Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
(October 17, 2019, Shanghai) The first prescription of the humanized anti-CD25 monoclonal antibody drug developed independently in China was issued in Zhongshan Hospital Affiliated to Fudan University today. The monoclonal antibody drug is independently developed by Sunshine Guojian, and is used for prevention of acute rejection after renal transplantation. Professor Zhu Tongyu, Vice President of Zhongshan Hospital Affiliated to Fudan University, said: “The first prescription of Xenopax means that Chinese transplant recipients can have access to more treatment options, and it also marks that the pharmaceutical capability in the field of immunotherapy in China has reached the international first-class level. Sunshine Guojian is expected to develop more and better biological preparations and make contribution to the improvement of China’s medical capability.”
(Shanghai, China, 29 July 2019) Today, China’s leading biopharmaceutical company Sunshine Pharmaceuticals Co., Ltd. (01530.HK) announced, the application for new drug production of the antibody fusion protein medicine YISAIPU pre-filled solution (common name: Recombinant Human Tumor Necrosis Factor-α ReceptorⅡ: IgG Fc Fusion Protein for Injection) independently developed by its Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd has been submitted to the National Medical Products Administration and accepted.
On May 17, 2019, Sunshine Guojian’s antibody drug YISAIPU was officially granted the GMP certificate in Indonesia.
On December 16, 2018, the friendly match between Sunshine Guojian football team and Quintiles football team went on smoothly under the warm invitation of two teams. After 90 minutes of fierce competition, Sunshine Guojian football team defeated their opponents 4-2.
After a series of strict and comprehensive reviews and assessment, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (referred to as “Sunshine Guojian”) was awarded the Grade A quality credit unit in the quality credit rating assessment of Shanghai pharmaceutical manufacturing enterprises.
On October 12, 2017, Sunshine Guojian’s YISAIPU was successfully granted the GMP certificate issued by the Mexican Ministry of Health.
On July 25 to 28, 2017, the Zhongzhi QC Team of Stock Solution Workshop C, on behalf of Sunshine Guojian Pharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as “Sunshine Guojian”), attended the 38th National Pharmaceutical Industry Quality Control Circle (QCC) Achievement Presentation and Exchange Meeting. Liu Wanbing, the team representative, published the achievement named “Optimization of Freezing Technology of Stock Solution,” which was awarded the first prize among 588 achievement projects presented on the site from 161 pharmaceutical companies in China.
Sunshine Guojian Pharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as “Sunshine Guojian”) accepted the 5-day comprehensive GMP inspection conducted by the National Food and Drug Administration of Colombia. The review results showed that Sunshine Guojian’s Stock Solution Zone A, Stock Solution B, Preparation Zone I and Preparation Zone III of Antibody Production Lines passed the official GMP certification review in Columbia.
On April 1, 2017, the 30,000L Antibody Production Line Preparation Zone III of Sunshine Guojian Pharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as Sunshine Guojian) was granted the “Certificate of Good Manufacturing Product for Pharmaceutical Products” (Certificate No.: SH20170009, valid until March 2022) by the China Food and Drug Administration.